Instil Bio (TIL) Competitors $19.06 +0.97 (+5.36%) Closing price 04:00 PM EasternExtended Trading$18.60 -0.46 (-2.41%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends TIL vs. CGEM, AUTL, ABVX, DNA, CMRX, KROS, MLYS, ANAB, MNMD, and RNACShould you be buying Instil Bio stock or one of its competitors? The main competitors of Instil Bio include Cullinan Therapeutics (CGEM), Autolus Therapeutics (AUTL), ABIVAX Société Anonyme (ABVX), Ginkgo Bioworks (DNA), Chimerix (CMRX), Keros Therapeutics (KROS), Mineralys Therapeutics (MLYS), AnaptysBio (ANAB), Mind Medicine (MindMed) (MNMD), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical products" industry. Instil Bio vs. Cullinan Therapeutics Autolus Therapeutics ABIVAX Société Anonyme Ginkgo Bioworks Chimerix Keros Therapeutics Mineralys Therapeutics AnaptysBio Mind Medicine (MindMed) Cartesian Therapeutics Instil Bio (NASDAQ:TIL) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations. Does the MarketBeat Community believe in TIL or CGEM? Instil Bio received 57 more outperform votes than Cullinan Therapeutics when rated by MarketBeat users. However, 83.33% of users gave Cullinan Therapeutics an outperform vote while only 50.50% of users gave Instil Bio an outperform vote. CompanyUnderperformOutperformInstil BioOutperform Votes10250.50% Underperform Votes10049.50% Cullinan TherapeuticsOutperform Votes4583.33% Underperform Votes916.67% Is TIL or CGEM more profitable? Cullinan Therapeutics' return on equity of -26.54% beat Instil Bio's return on equity.Company Net Margins Return on Equity Return on Assets Instil BioN/A -37.44% -25.08% Cullinan Therapeutics N/A -26.54%-25.32% Do institutionals and insiders believe in TIL or CGEM? 60.6% of Instil Bio shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 46.5% of Instil Bio shares are held by company insiders. Comparatively, 6.1% of Cullinan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media prefer TIL or CGEM? In the previous week, Cullinan Therapeutics had 6 more articles in the media than Instil Bio. MarketBeat recorded 7 mentions for Cullinan Therapeutics and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.89 beat Cullinan Therapeutics' score of 0.56 indicating that Instil Bio is being referred to more favorably in the media. Company Overall Sentiment Instil Bio Very Positive Cullinan Therapeutics Positive Which has more risk & volatility, TIL or CGEM? Instil Bio has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Which has preferable earnings and valuation, TIL or CGEM? Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInstil BioN/AN/A-$156.09M-$11.39-1.59Cullinan TherapeuticsN/AN/A-$153.16M-$3.03-3.00 Do analysts recommend TIL or CGEM? Instil Bio currently has a consensus target price of $114.00, suggesting a potential upside of 530.18%. Cullinan Therapeutics has a consensus target price of $32.86, suggesting a potential upside of 261.86%. Given Instil Bio's higher probable upside, research analysts plainly believe Instil Bio is more favorable than Cullinan Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00Cullinan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryInstil Bio beats Cullinan Therapeutics on 8 of the 15 factors compared between the two stocks. Remove Ads Get Instil Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TIL vs. The Competition Export to ExcelMetricInstil BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$118.06M$3.07B$5.64B$8.08BDividend YieldN/A1.47%4.89%4.04%P/E Ratio-1.5627.6723.7318.99Price / SalesN/A374.75382.31120.63Price / CashN/A168.6838.0534.64Price / Book0.523.466.904.26Net Income-$156.09M-$71.72M$3.18B$247.00M7 Day Performance-5.73%-1.13%6.75%-1.60%1 Month Performance-24.15%-10.35%0.15%-9.68%1 Year Performance43.69%-23.10%13.53%1.96% Instil Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TILInstil Bio3.2337 of 5 stars$19.06+5.4%$114.00+498.1%+50.1%$124.39MN/A-1.65410Upcoming EarningsAnalyst RevisionPositive NewsCGEMCullinan Therapeutics2.2786 of 5 stars$8.00-5.8%$32.50+306.3%-46.4%$465.82MN/A-2.8230AUTLAutolus Therapeutics3.1386 of 5 stars$1.75+1.2%$10.40+494.3%-63.3%$465.66M$10.09M-1.45330Upcoming EarningsABVXABIVAX Société Anonyme1.9313 of 5 stars$7.33-4.6%$38.67+427.5%-53.4%$464.47MN/A0.0061DNAGinkgo Bioworks0.8683 of 5 stars$8.04-2.4%$4.58-43.1%N/A$462.13M$227.04M-0.611,218Positive NewsCMRXChimerix2.634 of 5 stars$5.04-4.0%$9.00+78.6%+616.9%$453.28M$159,000.00-5.3690High Trading VolumeKROSKeros Therapeutics3.0409 of 5 stars$11.10+0.2%$42.33+281.4%-82.6%$449.63M$3.55M-2.13100Positive NewsMLYSMineralys Therapeutics2.559 of 5 stars$8.94-2.2%$27.00+202.0%+1.9%$445.53MN/A-2.4628Analyst ForecastNews CoverageANABAnaptysBio3.483 of 5 stars$14.64-13.0%$34.11+133.0%-32.0%$445.48M$57.17M-2.41100MNMDMind Medicine (MindMed)2.5603 of 5 stars$6.07-9.7%$26.33+333.8%-17.9%$445.13MN/A-2.6940Earnings ReportAnalyst RevisionRNACCartesian Therapeutics1.8907 of 5 stars$17.50-7.1%$42.86+144.9%-0.9%$444.76M$47.94M-0.3364Analyst ForecastGap Down Remove Ads Related Companies and Tools Related Companies CGEM Competitors AUTL Competitors ABVX Competitors DNA Competitors CMRX Competitors KROS Competitors MLYS Competitors ANAB Competitors MNMD Competitors RNAC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TIL) was last updated on 3/13/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Instil Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Instil Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TIL Stock Alerts